The trials will investigate datopotamab deruxtecan in combination with treatments including rilvegostomig, osimertinib, and chemotherapy in patients with nonsquamous non-small cell lung cancer.
More Stories
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a...
Navigating Distrust: Pharma in the Age of Social Media
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies...
Pharmaceutical Executive: February 2025 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive February 2025 issue in an interactive PDF format.
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
Meilog marks the first rapid-acting insulin biosimilar to gain FDA approval for the treatment of diabetes.
Limitations of Modern Databases: Q&A with Stavros Papadopoulos
The TileDB CEO discusses how the life sciences can overcome these limitations.
Preparing for Potential Vaccine Regulatory Changes
James Foster, CEO and co-founder of Virax Biolabs, discusses how the industry is preparing for potential regulatory changes to vaccine...